Media.Player

New Drug Treatment for Large B-Cell Lymphomas or Other Hematopoietic Malignancies

详细技术说明

Addressing the need for new treatment options for the patients with indolent lymphomas, UC San Diego researchers have developed a new method to detect and treat lymphomas, including forms of non-Hodgkin lymphoma, based on targeting tumor necrosis factor-alpha signaling (TNF-alpha; a multifunctional pro-inflammatory cytokine). This technology is focused on providing new treatment methods for the group of lymphoma patients characterized as resistant to conventional treatment. Specifically, this technology provides a means for: (a) detecting altered expression of microRNAs (i.e. miR21, miR155), phosphatase and tensin homolog deleted on chromosome ten (PTEN), and SH2-containing inositol phosphatase (SHIP-1; enzyme that hydrolyzes inositol 1,4,5-triphosphate) characteristic of hematopoietic malignancies; and (b) administering an effective amount of proven TNF-alpha inhibitors (i.e., neutralizing anti-TNF-alpha antibodies or soluble TNF-alpha receptor). The differential expression of a miR155 and SHIP-1 may provide a means to identify lymphoma patients that have a poor prognosis or will respond to treatment with a TNF-alpha inhibitor.

*Abstract

More than 60,000 people in the United States are diagnosed with lymphoma each year and the prognosis for those affected is usually poor. In many cases, patients may respond initially to first-line treatments (e.g. chemotherapy, radiotherapy), but subsequently suffer a relapse. In other cases, a patient may fail to respond to any treatment (refractory cancer). For patients diagnosed with relapsing cancers or patients resistance to conventional treatment, there are no optimal or preferred treatment options, resulting in a poor prognosis. Additional treatment options are needed for this group of lymphoma patients.

*IP Issue Date

Nov 11, 2014

*Principal Investigation

Name: Michael David

Department:

Name: Irene Pedersen

Department:

附加资料

Patent Number: US20110123524A1
Application Number: US2010919708A
Inventor: David, Michael | Pedersen, Irene Munk
Priority Date: 28 Jan 2008
Priority Number: US20110123524A1
Application Date: 2 Feb 2011
Publication Date: 26 May 2011
IPC Current: A61K0039395 | A61K003817 | A61P003500 | A61P003502
US Class: 4241331 | 4241421 | 4241581 | 5140193 | 5140196
Title: METHODS FOR TREATING HEMATOPOIETIC MALIGNANCIES
Usefulness: METHODS FOR TREATING HEMATOPOIETIC MALIGNANCIES
Summary: The methods are useful for treating a hematopoietic neoplasm in a mammalian subject. The hematopoietic neoplasm is a leukemia or a lymphoma. The lymphoma is a non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma is a diffuse large B-cell lymphoma (DLBCL) of an activated B-cell (ABC) subtype (all claimed). Leukemia comprises acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and hairy cell leukemia.
Novelty: Treating a hematopoietic neoplasm, e.g. leukemia or lymphoma, in a mammalian subject by administering to the mammalian subject an amount of a tumor necrosis factor (TNF)-alpha inhibitor

主要类别

诊断/治疗

细分类别

癌症/肿瘤

申请号码

8883155

其他

State Of Development

The inventors recorded elevated levels of miR-155 and consequent diminished SHIP-1 expression in diffuse large B cell lymphoma (DLBCL) that are the result of autocrine stimulation by the pro-inflammatory cytokine tumor necrosis factor (TNF). Standard anti-TNF regimens were sufficient to reduce miR-155 levels and restored SHIP-1 expression in DLBCL cells with an accompanying reduction in cell proliferation. This finding suggests that cytokine-regulated miRs may be a crucial link between inflammation and cancer and supports the feasibility of anti-TNF therapy as a novel and accessible treatment for DLBCL.

Related Materials

• An international patent application was filed on 22-Jan-2009 and published 06-Aug-2009 (Doc No. 2009097095). Consult this document for a detailed description of this offered technology.
• Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, Rickert RC, Gronbaek K, David M. Onco-miR-155 targets SHIP1 to Promote TNF-Alpha-Dependent Growth of B Cell Lymphomas. EMBO Mol Med. 2009 Aug;1(5):288-95.

Additional Technologies by these Inventors

• Polyclonal Antibodies to IRF3

Tech ID/UC Case

20873/2008-071-0

Related Cases

2008-071-0

国家/地区

美国